Search - tctmd.com

Displaying 21 - 40 of 62

Sort: Relevancy | Date

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

CAC Testing Improves Pretest Probability of Obstructive CAD

Michael O'Riordan

November 23, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Majority of SCAD Lesions Heal With Conservative Treatment

Michael O'Riordan

February 27, 2019

News Daily News

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Michael O'Riordan

February 25, 2019

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

Caitlin E. Cox

December 20, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

L.A. McKeown

June 12, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

Advertisement

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

CAC Testing Improves Pretest Probability of Obstructive CAD

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Majority of SCAD Lesions Heal With Conservative Treatment

CT Angiography Bests Functional Testing in Diabetic Patients With Chest Pain: PROMISE

Many PCI Patients Treated in China Have No Angina Symptoms

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content